Chronic treatment with angiotensin at1 receptor antagonists reduced serum but not bone TGF-β1 levels in ovariectomized rats

Canadian Journal of Physiology and Pharmacology

Volumn 87, Issue 1, 2009, Pages 51-55

  Li, Yong Qi ^a   Ji, Hui ^a   Shen, Yang ^a   Ding, Li Ju ^a   Zhuang, Pei ^a   Yang, Yu Lin ^a   Huang, Qiu Ju ^b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Angiotensin at1 receptor antagonists; Bone mineral density; Osteoporosis; Ovariectomized rats; Transforming growth factor 1 tgf 1

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ANGIOTENSIN 1 RECEPTOR; OSTEOCALCIN; TELMISARTAN; TRANSFORMING GROWTH FACTOR BETA1; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE; BONE DENSITY; CONTROLLED STUDY; FEMALE; FEMUR; LONG TERM CARE; LUMBAR VERTEBRA; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; TREATMENT DURATION;

ACID PHOSPHATASE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; BONE AND BONES; BONE DENSITY; FEMALE; HUMANS; ISOENZYMES; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY; TETRAZOLES; TRANSFORMING GROWTH FACTOR BETA1; VALINE;

EID: 65249158990     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/Y08-097     Document Type: Article

References (32)

1. Akinci, B., Bayraktar, F., Saklamaz, A., Demir, T., Yener, S., Comlekci, A., et al. 2007. Low transforming growth factor- beta! serum levels in idiopathic male osteoporosis. J. Endocrinol. Invest. 30(5): 350-355. PMID:17598964.
2. Benndorf, R.A., Rudolph, T., Appel, D., Schwedhelm, E., Maas, R., Schulze, F., et al. 2006. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism, 55(9): 1159-1164. doi:10.1016/j.metabol.2006.04.013. PMID:16919533.
3. Broulik, P.D., Tesar, V., Zima, T., and Jirsa, M. 2001. Impact of antihypertensive therapy on the skeleton: effects of enalapril and AT1 receptor antagonist losartan in female rats. Physiol. Res. 50(4): 353-358. PMID:11551140.
4. Cottone, S., Mule, G., Amato, F., Riccobene, R., Vadala, A., Lorito, M.C., et al. 2002. Amplified biochemical activation of endothelial function in hypertension associated with moderate to severe renal failure. J. Nephrol. 15(6): 643-648. PMID:12495277.
5. Deedwania, P.C., and Schmieder, R. 2006. Angiotensin receptor blockers: cardiovascular protection in the metabolic syndrome. J. Renin Angiotensin Aldosterone Syst. 7(Suppl 1): S12-S18. doi:10.3317/jraas.2006.018. PMID:16986230.
6. Derhaschnig, U., Shehata, M., Herkner, H., Bur, A., Woisetschlager, C., Laggner, A.N., et al. 2002. Increased levels of transforming growth factor-beta1 in essential hypertension. Am. J. Hypertens. 15(3): 207-211. doi:10.1016/S0895-7061(01) 02327-5. PMID:11939608.
7. Esmatjes, E., Flores, L., Inigo, P., Lario, S., Ruilope, L.M., and Campistol, J.M. 2001. Effect of losartan on TGF-beta1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. Nephrol. Dial. Transplant. 16(Suppl 1):90-93. PMID:11369831.
8. Finkelman, R.D., Linkhart, T.A., Mohan, S., Lau, K.H., Baylink, D.J., and Bell, N.H. 1991. Vitamin D deficiency causes a selective reduction in deposition of transforming growth factor beta in rat bone: possible mechanism for impaired osteoinduction. Proc. Natl. Acad. Sci. U.S.A. 88(9): 3657-3660. doi:10.1073/pnas.88.9.3657. PMID:2023915.
9. Finkelman, R.D., Bell, N.H., Strong, D.D., Demers, L.M., and Baylink, D.J. 1992. Ovariectomy selectively reduces the concentration of transforming growth factor beta in rat bone: implications for estrogen deficiency-associated bone loss. Proc. Natl. Acad. Sci. U.S.A. 89(24): 12190-12193. doi:10.1073/pnas.89. 24.12190. PMID:1465458.
10. Georgescu, C., Seck, T., Diel, I., Minne, H., Duncea, I., and Pfeilschifter, J. 2004. Bone matrix insulin-like growth factor (IGF)-I, IGF-II and transforming growth factor (TGF)-beta1 levels in men and postmenopausal women with osteoporosis: lack of association with circulating growth factors and bone mineral density. Rev. Med. Chir. Soc. Med. Nat. Iasi, 108(2): 281-286. PMID:15688799.
11. Grainger, D.J., Percival, J., Chiano, M., and Spector, T.D. 1999. The role of serum TGF-beta isoforms as potential markers of osteoporosis. Osteoporos. Int. 9(5): 398-404. doi:10.1007/s001980050163. PMID:10550458.
12. Gulcan, E., Gulcan, A., Toker, S., and Cosar, E. 2008. Are there any effects of angiotensin II receptor blockers on postmenopau- sal osteoporosis? Med. Hypotheses, 70(3): 701-702. doi:10.1016/j.mehy.2007.07.011. PMID:17714882.
13. Haznedaroglu, I.C., and Ozturk, M.A. 2003. Towards the understanding of the local hematopoietic bone marrow renin- angiotensin system. Int. J. Biochem. Cell Biol. 35(6): 867-880. doi:10.1016/S1357-2725(02)00278-9. PMID:12676173.
14. Janssens, K., ten Dijke, P., Janssens, S., and Van Hul, W. 2005. Transforming growth factor-beta1 to the bone. Endocr. Rev. 26(6): 743-774. doi:10.1210/er.2004-0001. PMID:15901668.
15. Jin, H., Yamamoto, N., Uchida, K., Terai, S., and Sakaida, I. 2007. Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino acid-defined diet. Biochem. Biophys. Res. Commun. 364(4):801-807. doi:10.1016/j.bbrc.2007.10.083. PMID:17963695.
16. Kalu, D.N. 1991. The ovariectomized rat model of postmenopausal bone loss. Bone Miner. 15(3): 175-191. doi:10.1016/0169- 6009(91)90124-I. PMID:1773131.
17. Karagiannis, A., Mikhailidis, D.P., Athyros, V.G., Kakafika, A.I., Tziomalos, K., Liberopoulos, E.N., et al. 2007. The role of re- nin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal? Expert Opin. Ther. Targets, 11(2): 191-205. doi:10.1517/14728222.11.2.191. PMID:17227234.
18. Kearney, P.M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P.K., and He, J. 2005. Global burden of hypertension: analysis of worldwide data. Lancet, 365(9455): 217-223. PMID: 15652604.
19. Mori, Y., Itoh, Y., and Tajima, N. 2007. Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity. Am. J. Hypertens. 20(4): 431-436.doi:10.1016/j.amjhyper.2006.09. 016. PMID:17386352.
20. Nicolas, V., Prewett, A., Bettica, P., Mohan, S., Finkelman, R.D., Baylink, D.J., et al. 1994. Age-related decreases in insulin-like growth factor-I and transforming growth factor-beta in femoral cortical bone from both men and women: implications for bone loss with aging. J. Clin. Endocrinol. Metab. 78(5): 1011-1016. doi:10.1210/jc.78.5.1011. PMID:8175953.
21. Parrinello, G., Licata, A., Colomba, D., Di Chiara, T., Argano, C., Bologna, P., et al. 2005. Left ventricular filling abnormalities and obesity-associated hypertension: relationship with overproduction of circulating transforming growth factor beta1. J. Hum. Hypertens. 19(7): 543-550. doi:10.1038/sj.jhh.1001864. PMID: 15944724.
22. Porreca, E., Di Febbo, C., Vitacolonna, E., Baccante, G., Di Castelnuovo, A., Angelini, A., et al. 2002. Transforming growth factor-beta1 levels in hypertensive patients: association with body mass index and leptin. Am. J. Hypertens. 15(9): 759-765. doi:10.1016/S0895-7061(02)02978-3. PMID:12219869.
23. Ren, P., Ji, H., Shao, Q., Chen, X., Han, J., and Sun, Y. 2007. Protective effects of sodium daidzein sulfonate on trabecular bone in ovariectomized rats. Pharmacology, 79(3): 129-136. doi:10. 1159/000098115. PMID:17179740.
24. Safar, M., Stimpel, M., and Zanchetti, A. 1994. Hypertension in postmenopausal women. Berlin: Springer-Verlag. PMID:17598964.
25. Scheen, A.J. 2004. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs, 64(22): 2537-2565. doi:10.2165/00003495-200464220-00004.PMID:15516153.
26. Smith, R.E.T., and Ashiya, M. 2007. Antihypertensive therapies. Nat. Rev. Drug Discov. 6(8): 597-598. doi:10.1038/nrd2354. PMID:17821828.
27. Suthanthiran, M., Li, B., Song, J.O., Ding, R., Sharma, V.K., Schwartz, J.E., et al. 2000. Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage. Proc. Natl. Acad. Sci. U.S.A. 97(7): 3479-3484. doi:10.1073/pnas. 050420897. PMID:10725360.
28. Usui, I., Fujisaka, S., Yamazaki, K., Takano, A., Murakami, S., Yamazaki, Y., et al. 2007. Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients. Diabetes Res. Clin. Pract. 77(2): 210-214. doi:10.1016/j.diabres.2006.11.014. PMID:17240472.
29. Wronski, T.J., Dann, L.M., Qi, H., and Yen, C.F. 1993. Skeletal effects of withdrawal of estrogen and diphosphonate treatment in ovariectomized rats. Calcif. Tissue Int. 53(3): 210-216. doi:10.1007/BF01321840. PMID:8242475.
30. Yoshiji, H., Kuriyama, S., Yoshii, J., Ikenaka, Y., Noguchi, R., Nakatani, T., et al. 2001. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology, 34(4 Pt 1): 745-750. PMID:11584371.
31. Zezina, L., Larsson, E., and Fellstrom, B. 2001. Candesartan cilex- etil reduces graft arteriosclerosis in aortic transplantation model in rat. Transpl. Immunol. 8(4): 245-251. doi:10.1016/S0966- 3274(01)00028-4. PMID:11316067.
32. Zhao, C., Wang, Y.Y., Xiao, Z.X., Wang, Y.P., and Zhang, Q.Y. 2007. The relationship between the gene polymorphism of TGF-beta1 and early renal injury in patients with essential hypertension, and the effect of the gene polymorphism of TGF- beta1 on the individual treatment with valsartan. Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 24(4): 428-431. PMID:17680535.